RxDoctor Payments Data

Manish Rungta, MD

Gastroenterology · Webster, TXNPI 1205847944

Payments from drug & device makers

$194,021in general payments, 2019–2025

Across 280 payments — averaging $692.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$190K
  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$486
  • Bristol Myers Squibb$366
  • Gilead$294
  • Mirum Pharmaceuticals, Inc.$150
  • plus $890 from 19 others

What the payments were for

  • Food & beverage$4,605100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$194,021 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$251,611
Medicare patients
488
Services billed
5,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin24$86,669
CreonLipase/Protease/Amylase33$83,697
LinzessLinaclotide37$40,291
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C52$7,080
Dexlansoprazole DrDexlansoprazole18$6,225
MovantikNaloxegol Oxalate15$6,137
Omeprazole374$3,620
Mesalamine ErMesalamine12$3,490
Famotidine212$2,813
ClenpiqSod Picosulf/Mag Ox/Citric Ac15$2,505
CholestyramineCholestyramine (With Sugar)18$1,572
Lansoprazole14$1,571
Lactulose45$1,365
Sucralfate56$1,274
Pantoprazole Sodium148$1,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,249$123,98770 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$150$93,74976 claims
Redhill Biopharma Inc.Movantik$41$6,13715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →